$13.5M Awarded to Stanford University and International Collaborators from the Gordon and Betty Moore Foundation to Advance the Science of Particle Accelerators
The Gordon and Betty Moore Foundation awarded $13.5 million to Stanford University and its international partners to take an innovative particle accelerator design dubbed the “accelerator-on-a-chip” and make it into a fully functional and scalable working prototype. This laser-driven particle accelerator could have a major impact on the physics community and on science in general by providing new particle and photon sources that are less expensive to build, address current infrastructure challenges and provide broader access to the scientific community.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151119005402/en/
The international effort to demonstrate a working prototype of an accelerator is based on experiments published in 2013 by the project’s two principal investigators, Dr. Robert Byer of Stanford University in Nature and Dr. Peter Hommelhoff of Friedrich-Alexander University Erlangen-Nuremberg in Physical Review Letters.
Drs. Byer and Hommelhoff each showed the potential for shrinking a laser-driven particle accelerator with the hope of building smaller and cheaper accelerators. Dr. Byer’s team injected high-energy electrons into a tiny device with a grating-like structure made from silica glass. They fired a pulse of laser light into this artfully-designed structure that produced a gain in electron acceleration that is 10 times greater than that achieved by conventional accelerators. Dr. Hommelhoff’s team, in a parallel approach, demonstrated that a laser could also be used to accelerate lower-energy, non-relativistic electrons. Both results taken together open the door to a compact particle accelerator. See how accelerator-on-a-chip works in this brief video.
“Based on our proposed revolutionary design, this prototype could set the stage for a new generation of ‘tabletop’ accelerators, with unanticipated discoveries in biology and materials science and potential applications in security scanning, medical therapy and x-ray imaging,” said Robert L. Byer, Ph.D., department of applied physics at Stanford University and co-principal investigator on the project.
The project brings together world renowned experts in accelerator physics, laser physics, nanophotonics and nanofabrication to develop a functional, scalable prototype accelerator within five years that will lead to electron and x-ray sources that are orders of magnitude smaller than current particle accelerators. Along with the leads at Stanford University and Friedrich-Alexander University, the international collaboration includes three national laboratories: SLAC National Accelerator Laboratory in Menlo Park, CA; Deutsches Elektronen-Synchrotron (DESY) in Hamburg, Germany; and the Paul Scherrer Institute in Villigen, Switzerland. It also includes five universities and one industry partner: University of California Los Angeles, Purdue University, University of Hamburg, the Swiss Federal Institute of Technology in Lausanne (EPFL) and Technical University of Darmstadt and Tech-X Corporation.
For the past 75 years, particle accelerators have been an essential tool for physics, chemistry, biology and medicine, leading to multiple Nobel-Prize winning discoveries. Without new accelerator technology to reduce the cost (in the billions) and size (several miles in length) and provide increased access for scientists, the field of particle physics and structural biology could stall.
“The impact of shrinking accelerators can be compared to the evolution of computers that once occupied entire rooms and now can be worn around your wrist. This advance means we may be able to expand particle acceleration into areas and communities that previously had no access to such resources,” said Dr. Peter Hommelhoff, professor of physics at Friedrich-Alexander University and co-principal investigator on the project.
The opportunities for discovery have never been greater, yet commitment and funding for science—from government, from industry, and from philanthropy—fall far short of what is needed today to accelerate progress into the future. While philanthropy alone cannot entirely fill this gap, the Gordon and Betty Moore Foundation believes in the importance of investing in basic research to fuel innovation that can have a significant impact on future generations. The foundation is one of the world’s largest private funders in science, including scientific research and technology development, investing more than $1.15B over the past 15 years.
“The accelerator-on-a-chip has terrific scientists pursuing a great idea. We’ll know they’ve succeeded when they advance from the proof-of-concept to a working prototype,” said Robert Kirshner, Ph.D., chief program officer of science at the Gordon and Betty Moore Foundation. “This research is risky, but the Moore Foundation is not afraid of risk when a novel approach holds the potential for a big advance in science. Making things small to produce immense returns is what Gordon Moore did for microelectronics.”
Gordon and Betty Moore Foundation fosters path-breaking scientific discovery, environmental conservation, patient care improvements and preservation of the special character of the Bay Area. Visit www.moore.org or follow @MooreFound.
The Gordon and Betty Moore Foundation
Stacey Bailey, 310-739-2859
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease18.7.2018 21:45 | Pressemelding
VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings showed lower cumulative days in hospital of 41 percent; p=0.02 (median 6.5 days vs. median 11 days) and a lower incidence of acute chest syndrome (ACS) by more than 60 percent; p=0.003 (13 of 152 patients [8.6%] had at least 1 ACS compared with 18 of 78 in the placebo group [23.1%]). The most common adverse reactions, occurring in great
Tigo Releases State-of-the-art Wireless Technology – Mesh – as the New Solar Communication Architecture for the TS4 Platform18.7.2018 19:41 | Pressemelding
Tigo®, pioneer of the smart modular Flex MLPE platform, today announced the release of its new Mesh communication architecture. This state-of-the-art wireless technology directly translates to customer benefits – including simplifying the solar design process and accelerating the commissioning steps. The complete Tigo solution uses a simple yet powerful data collection technology that covers the widest ranges of residential & commercial installations at the lowest cost. With Mesh and the recently announced Tigo Access Point (TAP), customers eliminate the need to address any roof obstruction or orientation constraint. To learn more about Mesh and TAP, register for Tigo’s free, online webinar “The Future of Solar is Wireless” on Wednesday July 25th, 2018 at 10am PDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180718005827/en/ Mesh is Tigo's proprietary software that allows each TS4 unit to act as a repeater, extending the
ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 201818.7.2018 17:21 | Pressemelding
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with li
Xilam: H1 2018 Revenue: +50%18.7.2018 16:00 | Pressemelding
Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2018 revenue of EUR 13,866 thousand, an increase of 50%. This increase represents an excellent performance, as it follows on the heels of growth of 54% in H1 2017. Revenue for the first part of this financial year breaks down as follows. In thousands of euros 30.06.2018 (1) 30.06.2017 Change New productions 8,465 4,571 +85% Catalogue 5,385 4,652 +16% Other 16 16 +0% Revenue and subsidies 13,866 9,239 +50% (1) Unaudited data. Remarkable success for new releases +85% Excellent H1 growth was driven by the two main businesses, New Productions and Catalogue. In New Productions, H1 deliveries generated record revenue of EUR 8,465 thousand, an 85% increase compared with H1 2017, and confirmed Xilam’s position as a major European animation company. Catalogue revenue was up 16% compared with H1 2017, thanks again to traditional TV channels and digital platforms, in both France and abroad. A fast-paced delivery schedule Thanks t
Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38 | Pressemelding
The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign
Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05 | Pressemelding
Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d